At study completion, sacubitril-valsartan was not superior to enalapril in either the global rank score or its individual components, but both treatment groups experienced significant improvements in HF classification, patient-reported outcomes, and NT-proBNP. This evidence concerns the gene NPPB and hydrops fetalis.